/ /

Lynda Charters
Potential uses for collagen crosslinking
Collagen crosslinking (CXL) is currently used to treat keratoconus, pellucid marginal degeneration, and post-LASIK ectasia, although it has not yet received FDA approval. Thomas John, MD, discussed the potential of the technology to treat corneal infections.
Collagen CXL in young keratoconic patients
Collagen crosslinking (CXL) provides good results in young patients with keratoconus, but the key to success in these young patients is rapid treatment upon presentation without waiting for disease progression, said Paolo Vinciguerra, MD.
Combining collagen CXL with intacs
Combination therapy of collage crosslinking (CXL) and intacs (Addition Technology, Inc.) may be a good treatment for mild-to-moderate keratoconus, according to David Rootman, MD.
Phakic IOLs: Good benefit-to-risk ratio
The benefit-to-risk ratio of phakic IOLs is well-balanced, and while there is a risk of decreased endothelial cell counts in some eyes with certain phakic IOLs, the optical quality achieved is very good, said Thomas Kohnen, MD, PhD.
Data: Lenticule extraction procedure predictable
Femtosecond laser lenticule extraction (small-incision lenticule extraction) performed to treat spherical myopia resulted in rapid and significant improvements in visual acuity. John Doane, MD, reported the preliminary data from the U.S. clinical trial.
Femtosecond laser for pediatric cataracts safe
Femtosecond laser-assisted cataract surgery in children with cataract was uneventful, safe, and resulted in good outcomes, despite being an off-label use of the technology, said Burkhard Dick, MD.
Examining anterior chamber phakic IOL for high myopia
The hydrophobic, acrylic, anterior chamber phakic IOL (AcrySof Cachet, Alcon Laboratories) performed well in a 5-year study of its safety and efficacy, according to Thomas Kohnen, MD, PhD. Most importantly, he said, the decrease in the corneal endothelial cell count was low and there were low rates of serious adverse events.
Scleral implant improving near vision with time
The preliminary results of the FDA multicenter trial of the Refocus Scleral Implant (Refocus Group) for presbyopia indicated that patients had a significant increase in the near visual acuity, and that the visual acuity improved over time, according to David Schanzlin, MD.
Visualization, guidance goes 3D
Three-dimensional (3D) visualization and guidance may be the future of lens IOL implantation. Douglas Koch, MD, posed two questions: Can surgeons eliminate marking for toric IOLs and eliminate the oculars on the microscope as well?
Honored Lecture: How glaucoma specialty continues to evolve
Glaucoma is now in a post-Renaissance period with far superior medications, better lasers, and the potential for individualized treatments for patients, according to Thomas W. Samuelson, MD.


View Results